Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation
Authors
Keywords
-
Journal
DRUG SAFETY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-03-13
DOI
10.1007/s40264-019-00810-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients
- (2018) Rabea Asleh et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort
- (2018) Hoda Abel Mahedi Mohamed et al. Oral Surgery Oral Medicine Oral Pathology Oral Radiology
- Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation
- (2017) Michael Charlton et al. TRANSPLANTATION
- Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials
- (2017) Jinyu Liu et al. PLoS One
- Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy
- (2016) H. S. Rugo et al. ANNALS OF ONCOLOGY
- Changes in lipid and carbohydrate metabolism under mTOR- and calcineurin-based immunosuppressive regimen in adult patients after liver transplantation
- (2016) Anca Zimmermann et al. European Journal of Internal Medicine
- Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma
- (2016) Edward K. Geissler et al. TRANSPLANTATION
- Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice
- (2016) Douglas E. Peterson et al. Cancer Medicine
- Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus
- (2015) Lutz Fischer et al. TRANSPLANTATION
- mTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?
- (2015) Hallvard Holdaas et al. Transplantation Reviews
- Rapamycin: One Drug, Many Effects
- (2014) Jing Li et al. Cell Metabolism
- Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients
- (2014) Marije C. Baas et al. TRANSPLANT INTERNATIONAL
- Strategies for the management of adverse events associated with mTOR inhibitors
- (2014) Bruce Kaplan et al. Transplantation Reviews
- Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial
- (2013) H. J. Eisen et al. AMERICAN JOURNAL OF TRANSPLANTATION
- A Central Role for mTOR in Lipid Homeostasis
- (2013) Dudley W. Lamming et al. Cell Metabolism
- mTOR in aging, metabolism, and cancer
- (2013) Marion Cornu et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
- (2013) John J Bissler et al. LANCET
- A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients
- (2013) Fabiana Martins et al. ORAL ONCOLOGY
- The Effect of Everolimus Versus Mycophenolate Upon Proteinuria Following Kidney Transplant and Relationship to Graft Outcomes
- (2012) A. C. Wiseman et al. AMERICAN JOURNAL OF TRANSPLANTATION
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
- (2012) D. A. Altomare et al. CURRENT MEDICINAL CHEMISTRY
- Cellular and physiological mechanisms of new-onset diabetes mellitus after solid organ transplantation
- (2012) M. Dong et al. DIABETIC MEDICINE
- A drug safety evaluation of everolimus in kidney transplantation
- (2012) Hallvard Holdaas et al. Expert Opinion On Drug Safety
- Adverse events associated with mTOR inhibitors
- (2012) Nicolas Pallet et al. Expert Opinion On Drug Safety
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
- (2012) David Neal Franz et al. LANCET
- Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
- (2011) Camillo Porta et al. EUROPEAN JOURNAL OF CANCER
- The use of Sirolimus should be restricted in liver transplantation
- (2011) Omar Massoud et al. JOURNAL OF HEPATOLOGY
- Inhibition of MTOR Disrupts Autophagic Flux in Podocytes
- (2011) D. P. Cina et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
- (2011) Klemens Budde et al. LANCET
- Early use of mammalian target of rapamycin inhibitors is an independent risk factor for incisional hernia development after liver transplantation
- (2011) Roberto Montalti et al. LIVER TRANSPLANTATION
- Surgical wound complications after heart transplantation
- (2011) Andreas Zuckermann et al. TRANSPLANT INTERNATIONAL
- Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials
- (2011) Liset H. M. Pengel et al. TRANSPLANT INTERNATIONAL
- Sirolimus and Proteinuria in Renal Transplant Patients: Evidence for a Dose-Dependent Effect on Slit Diaphragm-Associated Proteins
- (2011) Giovanni Stallone et al. TRANSPLANTATION
- Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month Study
- (2011) Hallvard Holdaas et al. TRANSPLANTATION
- Sirolimus-induced Pneumonitis Complicated by Pentamidine-induced Phospholipidosis in a Renal Transplant Recipient: A Case Report
- (2011) E.J. Filippone et al. TRANSPLANTATION PROCEEDINGS
- Is Proteinuria Reversible, After Withdrawal of Mammalian Target of Rapamycin Inhibitors?
- (2011) A. Arnau et al. TRANSPLANTATION PROCEEDINGS
- mTOR inhibitor–associated proteinuria in kidney transplant recipients
- (2011) Fritz Diekmann et al. Transplantation Reviews
- Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma
- (2010) Jesus Rodriguez-Pascual et al. ANTI-CANCER DRUGS
- mTOR inhibitor-associated dermatologic and mucosal problems
- (2010) Josep M. Campistol et al. CLINICAL TRANSPLANTATION
- Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
- (2010) V. P. Houde et al. DIABETES
- Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation
- (2010) Vivek N. Ahya et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Anaemia, microcytosis and sirolimus--is iron the missing link?
- (2010) S. Sofroniadou et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- The podocyte as a direct target of immunosuppressive agents
- (2010) E. Schonenberger et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Accelerated Wound Healing by mTOR Activation in Genetically Defined Mouse Models
- (2010) Cristiane H. Squarize et al. PLoS One
- Management of Side Effects of Sirolimus Therapy
- (2010) Giovanni Stallone et al. TRANSPLANTATION
- Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation
- (2010) Pamala A. Jacobson et al. TRANSPLANTATION
- Comparative Analysis of Adverse Events Requiring Suspension of mTOR Inhibitors: Everolimus versus Sirolimus
- (2010) A.I. Sánchez-Fructuoso et al. TRANSPLANTATION PROCEEDINGS
- Sirolimus is Associated With Impaired Hematopoiesis in Heart Transplant Patients? A Retrospective Analysis
- (2010) M.A. McDonald et al. TRANSPLANTATION PROCEEDINGS
- Sirolimus in Liver Transplant Recipients: A Large Single-Center Experience
- (2010) M. Vivarelli et al. TRANSPLANTATION PROCEEDINGS
- Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study
- (2009) Y. Lebranchu et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism
- (2009) N. Desai et al. BRITISH JOURNAL OF DERMATOLOGY
- Gonadal dysfunction and infertility in kidney transplant patients receiving sirolimus
- (2009) Yousef Boobes et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Posttransplant anemia: the role of sirolimus
- (2009) Steven Fishbane et al. KIDNEY INTERNATIONAL
- Molecular mechanisms of mTOR-mediated translational control
- (2009) Xiaoju Max Ma et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A Systematic Approach to Minimizing Wound Problems for De Novo Sirolimus-Treated Kidney Transplant Recipients
- (2009) Ho Yee Tiong et al. TRANSPLANTATION
- Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial
- (2009) Francesco P. Schena et al. TRANSPLANTATION
- Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients
- (2008) B. L. Kasiske et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Slowing Nephropathy Progression: Focus on Proteinuria Reduction
- (2008) G. L. Bakris Clinical Journal of the American Society of Nephrology
- mTOR Inhibition by Rapamycin Prevents -Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes
- (2008) M. Fraenkel et al. DIABETES
- Regulation of Pancreas Plasticity and Malignant Transformation by Akt Signaling
- (2008) Lynda Elghazi et al. GASTROENTEROLOGY
- Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients
- (2008) O. Johnston et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- mToR inhibitors-induced proteinuria: mechanisms, significance, and management
- (2008) Emmanuel Letavernier et al. Transplantation Reviews
- Upregulation of tissue factor expression and thrombogenic activity in human aortic smooth muscle cells by irradiation, rapamycin and paclitaxel
- (2007) Andreas Eisenreich et al. INTERNATIONAL IMMUNOPHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More